Kadimastem Ltd
KDST
Rank in Stocks
#40945
Kadimastem Ltd is a biopharmaceutical company focused on pioneering... Kadimastem Ltd is a biopharmaceutical company focused on pioneering regenerative medical treatments. These therapies are developed using cells sourced from human embryonic stem cells, primarily targeting neurodegenerative diseases. Its development pipeline features AstroRx, a clinical-grade human astrocyte product currently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. Additionally, the company is advancing IsletRx, a clinical-grade pancreatic islet cell therapy intended for the treatment of diabetes. Incorporated in 2008, Kadimastem is headquartered in Ness Ziona, Israel.
Share Price
$12.16
Last synced: 2025-10-30
Market Cap
$50.98K
Change (1 day)
-0.10%
Change (1 year)
69.56%
Country
IL
Trade Kadimastem Ltd (KDST)
Category
Healthcare
Operating Margin for Kadimastem Ltd (KDST)
Operating Margin as of 2026 TTM: 0.00%
According to Kadimastem Ltd latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Kadimastem Ltd from 2026 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.